The JAK1 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-mediated gene-disrupted polyclonal population derived from the 143B human osteosarcoma cell line, providing a loss-of-function model for studying JAK1-dependent signaling. This polyclonal knockout product enriches the pool of edited cells to facilitate the analysis of JAK1 function without the selection of a single clonal isolate, maintaining a representation of diverse editing events across the population while effectively disrupting target-gene expression.
The 143B cell line is a highly metastatic osteosarcoma model originating from a human bone cancer, characterized by KRAS transformation and robust metastatic potential. This cell line is widely employed to investigate mechanisms of osteosarcoma progression, metastasis, and therapeutic response. Its aggressive phenotype makes it a particularly relevant platform for dissecting the contributions of specific signaling nodes, such as JAK1, to cancer cell behavior.
JAK1 encodes a non-receptor tyrosine kinase that associates with the intracellular domains of cytokine receptors, including those for interleukin-6 (IL-6), interferon-gamma (IFN??), interleukin-2 (IL-2), and interleukin-4 (IL-4). Upon ligand-induced receptor activation, JAK1 undergoes autophosphorylation and phosphorylates receptor tyrosine residues, creating docking sites for STAT transcription factors such as STAT1, STAT3, STAT5, and STAT6. Phosphorylated STATs dimerize and translocate to the nucleus to regulate the expression of target genes involved in proliferation (c-Myc, Cyclin D1), survival (Bcl-xL), and immune modulation (IRF1, SOCS1, SOCS3). JAK1 also interacts with other Janus kinase family members JAK2, JAK3, and TYK2, as well as adaptor proteins like gp130 and receptor subunits IL-2R?? and IL-4R??, facilitating cross-talk with the PI3K-AKT pathway and integrating cytokine signals with growth factor inputs from EGF and PDGF.
In the context of osteosarcoma, aberrant JAK1-STAT signaling has been implicated in tumor growth, metastatic dissemination, and resistance to apoptosis. The 143B cell line, with its KRAS-driven metastatic background, provides an experimentally tractable system to isolate the role of JAK1 in these processes. Disruption of JAK1 in this model allows researchers to examine how loss of JAK1 impacts cytokine responsiveness, cell migration, invasion, and downstream transcriptional programs, thereby clarifying the kinase??s contribution to the malignant phenotype of osteosarcoma.
This knockout product is suitable for a broad range of applications, including cytokine stimulation experiments followed by Western blotting for phospho-JAK1 or phospho-STAT proteins, flow cytometric detection of STAT phosphorylation, RT-qPCR analysis of STAT target gene expression, and functional assays such as cell proliferation, apoptosis, and wound healing/migration. It also serves as a valuable isogenic background for co-immunoprecipitation studies of JAK1-STAT interactions and for screening small-molecule JAK inhibitors. The model is particularly useful for immuno-oncology and drug development research focusing on JAK1-dependency in bone cancers and inflammatory disorders. For additional details or inquiries, please contact Ascent Research.
